This inventor holds 6 USPTO granted patents and 1 EPO patent. Top assignees: Astrazeneca Ab, Acturum Real Estate Ab, Arcturum Real Estate Ab. Active years: 2017-2026.
Company Filing History:
4 out of 1,531 
1 out of 1 
1 out of 1 Years Active: 2017-2026
Title: Katharina Högdin: Innovator in Pharmaceutical Chemistry
Introduction
Katharina Högdin is a prominent inventor based in Knivsta, Sweden. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for the treatment of various medical conditions. With a total of 6 patents to her name, her work has the potential to impact the lives of many patients.
Latest Patents
Högdin's latest patents include innovative prodrugs of NMDA antagonists, specifically (S)-1-phenyl-2-(pyridin-2-yl)ethanamine. These compounds are particularly useful for treating depression, especially major depressive disorder, and pain. Another notable patent involves bis(sulfonamide) derivatives, which serve as mPGES inhibitors. This invention relates to compounds that can be used as medicaments for treating diseases where modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation, and cancer.
Career Highlights
Throughout her career, Katharina Högdin has worked with leading companies in the pharmaceutical industry, including AstraZeneca AB and Arcturum Real Estate AB. Her experience in these organizations has allowed her to develop her expertise and contribute to groundbreaking research.
Collaborations
Högdin has collaborated with notable colleagues such as Annika Kers and Gunnar Nordvall. These partnerships have further enriched her research and development efforts in the pharmaceutical field.
Conclusion
Katharina Högdin is a remarkable inventor whose work in pharmaceutical chemistry continues to pave the way for innovative treatments. Her contributions, particularly in the area of NMDA antagonists and mPGES inhibitors, highlight her commitment to improving patient care through scientific advancements.